# A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

> **NCT06224413** · — · RECRUITING · sponsor: **Genetix Biotherapeutics Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Cerebral Adrenoleukodystrophy (CALD)

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT06224413
- **Lead sponsor:** Genetix Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2047-12-30
- **Final completion:** 2047-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06224413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06224413, "A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06224413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*